Find Clinical Trials | Cedars-Sinai

154 results found

Melanoma

Pfizer Inc, C4901001, Phase 1A/B, Open Label, Melanoma ,Solid Tumor, PF-07799544

-Primary Objective: This is a first-in-human, open-label, Phase 1a/b master protocol to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of PF-07799544 (also known as ARRY-134) as a single agent and in ...

Other Hematopoietic

Merck,MK2140-010,Ph 3,Randomized, Lymphoma, Zilovertamab vedotin + R-CHP vs R-Chop

Primary Objective: To compare zilovertamab vedotin plus R-CHP with R-CHOP with respect to progression-free survival (PFS) per Lugano response criteria as assessed by blinded independent central review (BICR). Hypothesis (H1): Zilovertamab vedotin plus R-CHP is superior to ...

Melanoma

Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) ...

Lung

SWOG, S1800E, PhII/III, Randomized, Doetaxel + Ramucirumab +/- Cemiplimab, NSCLC

Primary Objective: The primary objective of the study is to compare overall survival (OS) between participants randomized to docetaxel and ramucirumab with or without cemiplimab (REGN2810) who have acquired resistance to platinum-based chemotherapy and ...